



Taltz (ixekizumab)
Prior Authorization Request Form



Caterpillar Prescription Drug Benefit
 Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ **MEMBER'S FIRST NAME:** _____

Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

URGENT

MEMBER INFORMATION		
LAST NAME:	FIRST NAME:	
PHONE NUMBER:	DATE OF BIRTH:	
STREET ADDRESS:		
CITY:	STATE:	ZIP CODE:
PATIENT INSURANCE ID NUMBER:		

MALE FEMALE HEIGHT (IN/CM): _____ WEIGHT (LB/KG): _____ ALLERGIES: _____

IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE FOLLOWING LINK: [HTTPS://MAGELLANRX.COM/MEMBER/EXTERNAL/COMMERCIAL/COMMON/DOC/EN-US/PHI_DISCLOSURE_AUTHORIZATION.PDF](https://MAGELLANRX.COM/MEMBER/EXTERNAL/COMMERCIAL/COMMON/DOC/EN-US/PHI_DISCLOSURE_AUTHORIZATION.PDF)

PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE): _____

AUTHORIZED REPRESENTATIVE'S PHONE NUMBER: _____

PRESCRIBER INFORMATION		
LAST NAME:	FIRST NAME:	
PRESCRIBER SPECIALTY:	EMAIL ADDRESS:	
NPI NUMBER:	DEA NUMBER:	
PHONE NUMBER:	FAX NUMBER:	
STREET ADDRESS:		
CITY:	STATE:	ZIP CODE:
REQUESTOR (if different than prescriber):	OFFICE CONTACT PERSON:	

MEDICATION OR MEDICAL DISPENSING INFORMATION			
MEDICATION NAME:			
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:
<input type="checkbox"/> NEW THERAPY	<input type="checkbox"/> RENEWAL	IF RENEWAL: DATE THERAPY INITIATED:	
DURATION OF THERAPY (SPECIFIC DATES):			

Continued on next page.





**Taltz (ixekizumab)
Prior Authorization Request Form**



Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ MEMBER'S FIRST NAME: _____

1. HAS THE PATIENT TRIED ANY OTHER MEDICATIONS FOR THIS CONDITION? <input type="checkbox"/> YES (if yes, complete below) <input type="checkbox"/> NO		
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE): 	DURATION OF THERAPY (SPECIFY DATES): 	RESPONSE/REASON FOR FAILURE/ALLERGY:
2. LIST DIAGNOSES:		ICD-10:
<input type="checkbox"/> Plaque psoriasis <input type="checkbox"/> Psoriatic arthritis <input type="checkbox"/> Ankylosing spondylitis <input type="checkbox"/> Nonradiographic Axial Spondyloarthritis: <input type="checkbox"/> Other Diagnosis _____ ICD-10 Code(s): _____		
3. REQUIRED CLINICAL INFORMATION: PLEASE PROVIDE ALL RELEVANT CLINICAL INFORMATION TO SUPPORT A PRIOR AUTHORIZATION.		
Clinical Information: Initial Request: Is drug being used as part of a clinical trial? <input type="checkbox"/> Yes <input type="checkbox"/> No Is the patient on concurrent treatment with another TNF inhibitor? <input type="checkbox"/> Yes <input type="checkbox"/> No Has the patient tried and had an inadequate response to a three month trial of Enbrel?* <input type="checkbox"/> Yes <input type="checkbox"/> No <i>*Must provide documentation, including trial dates.</i> Has the patient tried and had an inadequate response to a three month trial of Humira?* <input type="checkbox"/> Yes <input type="checkbox"/> No <i>*Must provide documentation, including trial dates.</i> Is Taltz prescribed by a dermatologist? <input type="checkbox"/> Yes <input type="checkbox"/> No Is Taltz prescribed by a rheumatologist? <input type="checkbox"/> Yes <input type="checkbox"/> No		
For Request Plaque Psoriasis, also answer the following: Does the patients have plaques covering greater than or equal to 3% of their body surface area (BSA)? <input type="checkbox"/> Yes <input type="checkbox"/> No Does the patient have plaques covering less than 3% of BSA with involvement of palms, soles, head and neck, or genitalia which causes disruption of normal activities? <input type="checkbox"/> Yes <input type="checkbox"/> No Has the patient had an inadequate response to a topical therapy (e.g., corticosteroids, anthralin, calcipotriene tazarotene)? <input type="checkbox"/> Yes <input type="checkbox"/> No If "yes" to the above question, please provide supporting documentation, including which agent(s) have been tried and trial dates: _____ Select if the patient has had an inadequate response to previous treatment with the following phototherapies: <input type="checkbox"/> Psoralens with UVA light (PUVA) <input type="checkbox"/> UVB with coal tar Please provide supporting documentation, including which agent(s) have been tried and trial dates: _____		





Taltz (ixekizumab)
Prior Authorization Request Form



Caterpillar Prescription Drug Benefit
 Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ MEMBER'S FIRST NAME: _____

Select if the patient has tried and had an inadequate response to the following oral systemic therapies:

- Acitretin
- Methotrexate
- Cyclosporine

Please provide supporting documentation, including which agent(s) have been tried and trial dates: _____

Select if the patient has a contraindication to ALL of the following oral systemic therapies:*

- Acitretin
- Methotrexate
- Cyclosporine

**Please submit documentation of the contraindications to all three drugs.*

For Request of Ankylosing Spondylitis, also answer the following:

Has patient had a trial of at least two (2) NSAIDs OR has patient had a trial of one NSAID AND methotrexate?

Yes No

For Request of Nonradiographic Axial Spondyloarthritis, also answer the following:

Did the patient's back pain begin before age 45 years? Yes No

Does the patient have objective signs of inflammation by presence of sacroiliitis on MRI?

Yes No *Please submit MRI report.*

Does the patient have objective signs of inflammation by presence of an elevated C-reactive protein level?

Yes No *Please submit lab report*

Has the patient had an inadequate response to at least two different NSAIDs for at least 4 weeks?

Yes No *Please submit documentation.*

Is the patient intolerant of NSAIDs? Yes No *Please submit documentation.*

Does the patient have radiographic sacroiliitis (per 1984 modified New York criteria)? Yes No *Please submit imaging (x-ray) report.*

Has the patient received prior treatment with other biologic therapy, TNF inhibitors or other immunomodulatory agents? Yes No

Renewal Requests:

Is Taltz prescribed by a dermatologist? Yes No

Is Taltz prescribed by a rheumatologist? Yes No

Is patient continuing to respond to therapy? Yes No *Please submit documentation.*





Taltz (ixekizumab)
Prior Authorization Request Form
 Caterpillar Prescription Drug Benefit
 Phone: 877-228-7909 Fax: 800-424-7640



MEMBER'S LAST NAME: _____ **MEMBER'S FIRST NAME:** _____

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: Not all drugs/diagnosis are covered on all plans. This request may be denied unless all required information is received.

ATTESTATION: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

Prescriber Signature or Electronic I.D. Verification: _____ **Date:** _____

CONFIDENTIALITY NOTICE: The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.

FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Magellan Rx Management Prior Authorization Program
 Attn: CP – 4201
 P.O. Box 64811
 St. Paul, MN 55164-0811

